Evidence map›Paper›PMID 36585278›Full record

ArticleVaccine2023

Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate.

Stephen Tottey, Yoko Shoji, R Mark Jones, Konstantin Musiychuk, Jessica A Chichester, Kazutoyo Miura, Luwen Zhou, Shwu-Maan Lee, Jordan Plieskatt, Yimin Wu and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Stephen TotteyFraunhofer USA Center Mid-Atlantic, Biotechnology Division, 9 Innovation Way, Newark, DE 19711, USA.
Yoko ShojiFraunhofer USA Center Mid-Atlantic, Biotechnology Division, 9 Innovation Way, Newark, DE 19711, USA.
R Mark JonesFraunhofer USA Center Mid-Atlantic, Biotechnology Division, 9 Innovation Way, Newark, DE 19711, USA.
Konstantin MusiychukFraunhofer USA Center Mid-Atlantic, Biotechnology Division, 9 Innovation Way, Newark, DE 19711, USA.
Jessica A ChichesterFraunhofer USA Center Mid-Atlantic, Biotechnology Division, 9 Innovation Way, Newark, DE 19711, USA.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD 20852, USA.
Luwen ZhouLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD 20852, USA.
Shwu-Maan LeePATH's Malaria Vaccine Initiative, Washington, DC 20001, USA.
Jordan PlieskattPATH's Malaria Vaccine Initiative, Washington, DC 20001, USA.
Yimin WuPATH's Malaria Vaccine Initiative, Washington, DC 20001, USA.
Carole A LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD 20852, USA.
Stephen J StreatfieldFraunhofer USA Center Mid-Atlantic, Biotechnology Division, 9 Innovation Way, Newark, DE 19711, USA. Electronic address: sstreatfield@fraunhofer.org.
Vidadi YusibovFraunhofer USA Center Mid-Atlantic, Biotechnology Division, 9 Innovation Way, Newark, DE 19711, USA.
Fraunhofer USA · USU.S. President's Malaria Initiative · USNational Institutes of Health · USNational Institute of Allergy and Infectious Diseases · US

Funding

Host Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6M
Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

Malaria kills around 409,000 people a year, mostly children under the age of five. Malaria transmission-blocking vaccines work to reduce malaria prevalence in a community and have the potential to be part of a multifaceted approach required to eliminate the parasites causing the disease. Pfs25 is a leading malaria transmission-blocking antigen and has been successfully produced in a plant expression system as both a subunit vaccine and as a virus-like particle. This study demonstrates an improved version of the virus-like particle antigen display molecule by eliminating known protease sites from the prior A85 variant. This re-engineered molecule, termed B29, displays three times the number of Pfs25 antigens per virus-like particle compared to the original Pfs25 virus-like particle. An improved purification scheme was also developed, resulting in a substantially higher yield and improved purity. The molecule was evaluated in a mouse model and found to induce improved transmission-blocking activity at lower doses and longer durations than the original molecule.

Indexed as

MalariaMalaria, FalciparumMalaria VaccinesAnimalsAntibodies, ProtozoanAntigens, ProtozoanMicePlasmodium falciparumProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanMalaria VaccinesProtozoan ProteinsMalariaPfs25Plant-based vaccinePlasmodium falciparumTransmission-blocking vaccineVirus-like particle

Identifiers

PMID36585278
PMCPMC9888754
OpenAlexW4313340033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.